{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Kampo medicine", "general fatigue", "herbal medicine", "long COVID"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "35743993", "DateCompleted": {"Year": "2022", "Month": "06", "Day": "27"}, "DateRevised": {"Year": "2022", "Month": "12", "Day": "07"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "05", "Day": "28"}], "Language": ["eng"], "ELocationID": ["730", "10.3390/medicina58060730"], "Journal": {"ISSN": "1648-9144", "JournalIssue": {"Volume": "58", "Issue": "6", "PubDate": {"Year": "2022", "Month": "May", "Day": "28"}}, "Title": "Medicina (Kaunas, Lithuania)", "ISOAbbreviation": "Medicina (Kaunas)"}, "ArticleTitle": "Application of Kampo Medicines for Treatment of General Fatigue Due to Long COVID.", "Abstract": {"AbstractText": ["Evidence regarding treatment for the acute phase of COVID-19 has been accumulating, but specific treatment for long COVID/post-COVID-19 condition has not yet been established. Treatment with herbal medicine might be one treatment option for long COVID, but there has been little research on the effectiveness of herbal medicine for long COVID. The aim of this study was to clarify the prescription patterns of Kampo medicines, which are herbal medicines that originated in China and were developed in Japan, for the treatment of general fatigue due to long COVID. A retrospective descriptive study was performed for patients who visited a COVID-19 aftercare clinic established in Okayama University Hospital during the period from Feb 2021 to Dec 2021 with a focus on symptoms accompanying general fatigue and prescriptions of Kampo medicine. Among the clinical data obtained from medical records of 195 patients, clinical data for 102 patients with general fatigue and accompanying symptoms were analyzed. The patients had various symptoms, and the most frequent symptoms accompanying general fatigue were dysosmia, dysgeusia, headache, insomnia, dyspnea, and hair loss. Prescriptions of Kampo medicine accounted for 24.1% of the total prescriptions (<i>n</i> = 609). The most frequently prescribed Kampo medicine was hochuekkito (71.6%) and other prescribed Kampo medicines were tokishakuyakusan, ryokeijutsukanto, juzentaihoto, hangekobokuto, kakkonto, ninjin'yoeito, goreisan, rikkunshito, and keishibukuryogan. Since the pathophysiology of general fatigue after an infectious disease is, in general, considered a qi deficiency in Kampo medicine, treatments with such compensation agents can be the major prescription as a complement for the qi. In conclusion, Kampo medicine can be one of the main pharmacological treatments for long COVID accompanying general fatigue."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan."}], "LastName": "Tokumasu", "ForeName": "Kazuki", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan."}, {"Identifier": [], "Affiliation": "Clinical and Educational Center for Kampo Medicine, Okayama University Hospital, Okayama 700-8558, Japan."}], "LastName": "Ueda", "ForeName": "Keigo", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan."}], "LastName": "Honda", "ForeName": "Hiroyuki", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan."}], "LastName": "Sunada", "ForeName": "Naruhiko", "Initials": "N"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan."}], "LastName": "Sakurada", "ForeName": "Yasue", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan."}], "LastName": "Matsuda", "ForeName": "Yui", "Initials": "Y"}, {"Identifier": ["0000-0001-9972-791X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan."}], "LastName": "Nakano", "ForeName": "Yasuhiro", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan."}], "LastName": "Hasegawa", "ForeName": "Toru", "Initials": "T"}, {"Identifier": ["0000-0001-6015-6128"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan."}], "LastName": "Otsuka", "ForeName": "Yuki", "Initials": "Y"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan."}, {"Identifier": [], "Affiliation": "Clinical and Educational Center for Kampo Medicine, Okayama University Hospital, Okayama 700-8558, Japan."}], "LastName": "Obika", "ForeName": "Mikako", "Initials": "M"}, {"Identifier": ["0000-0002-5086-1891"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan."}], "LastName": "Hagiya", "ForeName": "Hideharu", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan."}], "LastName": "Kataoka", "ForeName": "Hitomi", "Initials": "H"}, {"Identifier": ["0000-0001-7014-9095"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan."}, {"Identifier": [], "Affiliation": "Clinical and Educational Center for Kampo Medicine, Okayama University Hospital, Okayama 700-8558, Japan."}], "LastName": "Otsuka", "ForeName": "Fumio", "Initials": "F"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Medicina (Kaunas)", "NlmUniqueID": "9425208", "ISSNLinking": "1010-660X"}, "MeshHeadingList": [{"QualifierName": ["complications"], "DescriptorName": "COVID-19"}, {"QualifierName": ["drug therapy", "etiology"], "DescriptorName": "Fatigue"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Medicine, Kampo"}, {"QualifierName": [], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Retrospective Studies"}, {"QualifierName": [], "DescriptorName": "Post-Acute COVID-19 Syndrome"}, {"QualifierName": [], "DescriptorName": "COVID-19 Drug Treatment"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Nuzzo J.B., Gostin L.O. The First 2 Years of COVID-19: Lessons to Improve Preparedness for the Next Pandemic. JAMA. 2022;327:217\u2013218. doi: 10.1001/jama.2021.24394.", "ArticleIdList": ["10.1001/jama.2021.24394", "34989763"]}, {"Citation": "Carfi A., Bernabei R., Landi F., Gemelli Against C.-P.-A.C.S.G. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324:603\u2013605. doi: 10.1001/jama.2020.12603.", "ArticleIdList": ["10.1001/jama.2020.12603", "PMC7349096", "32644129"]}, {"Citation": "Shah W., Hillman T., Playford E.D., Hishmeh L. Managing the long term effects of COVID-19: Summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136. doi: 10.1136/bmj.n136.", "ArticleIdList": ["10.1136/bmj.n136", "33483331"]}, {"Citation": "Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V., WHO Clinical Case Definition Working Group on Post-COVID-19 Condition A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 2021;22:e102\u2013e107. doi: 10.1016/S1473-3099(21)00703-9.", "ArticleIdList": ["10.1016/S1473-3099(21)00703-9", "PMC8691845", "34951953"]}, {"Citation": "Anaya J.M., Rojas M., Salinas M.L., Rodriguez Y., Roa G., Lozano M., Rodriguez-Jimenez M., Montoya N., Zapata E., Post-COVID Study Group et al. Post-COVID syndrome. A case series and comprehensive review. Autoimmun. Rev. 2021;20:102947. doi: 10.1016/j.autrev.2021.102947.", "ArticleIdList": ["10.1016/j.autrev.2021.102947", "PMC8428988", "34509649"]}, {"Citation": "Lopez-Leon S., Wegman-Ostrosky T., Perelman C., Sepulveda R., Rebolledo P.A., Cuapio A., Villapol S. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci. Rep. 2021;11:16144. doi: 10.1038/s41598-021-95565-8.", "ArticleIdList": ["10.1038/s41598-021-95565-8", "PMC8352980", "34373540"]}, {"Citation": "Miyazato Y., Morioka S., Tsuzuki S., Akashi M., Osanai Y., Tanaka K., Terada M., Suzuki M., Kutsuna S., Saito S., et al. Prolonged and Late-Onset Symptoms of Coronavirus Disease 2019. Open Forum Infect. Dis. 2020;7:ofaa507. doi: 10.1093/ofid/ofaa507.", "ArticleIdList": ["10.1093/ofid/ofaa507", "PMC7665672", "33230486"]}, {"Citation": "Otsuka Y., Tokumasu K., Nakano Y., Honda H., Sakurada Y., Sunada N., Omura D., Hasegawa K., Hagiya H., Obika M., et al. Clinical Characteristics of Japanese Patients Who Visited a COVID-19 Aftercare Clinic for Post-Acute Sequelae of COVID-19/Long COVID. Cureus. 2021;13:e18568. doi: 10.7759/cureus.18568.", "ArticleIdList": ["10.7759/cureus.18568", "PMC8571943", "34760415"]}, {"Citation": "Sakurada Y., Sunada N., Honda H., Tokumasu K., Otsuka Y., Nakano Y., Hanayama Y., Furukawa M., Hagiya H., Otsuka F. Serial Changes of Long COVID Symptoms and Clinical Utility of Serum Antibody Titers for Evaluation of Long COVID. J. Clin. Med. 2022;11:1309. doi: 10.3390/jcm11051309.", "ArticleIdList": ["10.3390/jcm11051309", "PMC8911256", "35268400"]}, {"Citation": "Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601\u2013615. doi: 10.1038/s41591-021-01283-z.", "ArticleIdList": ["10.1038/s41591-021-01283-z", "PMC8893149", "33753937"]}, {"Citation": "Raveendran A.V., Jayadevan R., Sashidharan S. Long COVID: An overview. Diabetes Metab. Syndr. 2021;15:869\u2013875. doi: 10.1016/j.dsx.2021.04.007.", "ArticleIdList": ["10.1016/j.dsx.2021.04.007", "PMC8056514", "33892403"]}, {"Citation": "Simani L., Ramezani M., Darazam I.A., Sagharichi M., Aalipour M.A., Ghorbani F., Pakdaman H. Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19. J. Neurovirol. 2021;27:154\u2013159. doi: 10.1007/s13365-021-00949-1.", "ArticleIdList": ["10.1007/s13365-021-00949-1", "PMC7852482", "33528827"]}, {"Citation": "Komaroff A.L., Bateman L. Will COVID-19 Lead to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome? Front. Med. 2020;7:606824. doi: 10.3389/fmed.2020.606824.", "ArticleIdList": ["10.3389/fmed.2020.606824", "PMC7848220", "33537329"]}, {"Citation": "Davis S., Samudra M., Dhamija S., Chaudhury S., Saldanha D. Stigma associated with COVID-19. Ind. Psychiatry J. 2021;30:S270\u2013S272. doi: 10.4103/0972-6748.328827.", "ArticleIdList": ["10.4103/0972-6748.328827", "PMC8611585", "34908707"]}, {"Citation": "Fukuda K., Straus S.E., Hickie I., Sharpe M.C., Dobbins J.G., Komaroff A. The chronic fatigue syndrome: A comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann. Intern. Med. 1994;121:953\u2013959. doi: 10.7326/0003-4819-121-12-199412150-00009.", "ArticleIdList": ["10.7326/0003-4819-121-12-199412150-00009", "7978722"]}, {"Citation": "Carruthers B.M., Jain A.K., De Meirleir K.L., Peterson D.L., Klimas N.G., Lerner A.M., Bested A.C., Flor-Henry P., Joshi P., Powles A.C.P., et al. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. J. Chronic Fatigue Syndr. 2003;11:7\u2013115. doi: 10.1300/J092v11n01_02.", "ArticleIdList": ["10.1300/J092v11n01_02"]}, {"Citation": "Myalgic Encephalomyelitis (or Encephalopathy)/Chronic Fatigue Syndrome: Diagnosis and Management. National Institute for Health and Care Excellence: Guidelines; National Institute for Health and Care Excellence; London, UK: 2021."}, {"Citation": "White P.D., Goldsmith K.A., Johnson A.L., Potts L., Walwyn R., DeCesare J.C., Baber H.L., Burgess M., Clark L.V., Cox D.L., et al. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): A randomised trial. Lancet. 2011;377:823\u2013836. doi: 10.1016/S0140-6736(11)60096-2.", "ArticleIdList": ["10.1016/S0140-6736(11)60096-2", "PMC3065633", "21334061"]}, {"Citation": "Whiting P., Bagnall A.M., Sowden A.J., Cornell J.E., Mulrow C.D., Ramirez G. Interventions for the treatment and management of chronic fatigue syndrome: A systematic review. JAMA. 2001;286:1360\u20131368. doi: 10.1001/jama.286.11.1360.", "ArticleIdList": ["10.1001/jama.286.11.1360", "11560542"]}, {"Citation": "Afari N., Buchwald D. Chronic fatigue syndrome: A review. Am. J. Psychiatry. 2003;160:221\u2013236. doi: 10.1176/appi.ajp.160.2.221.", "ArticleIdList": ["10.1176/appi.ajp.160.2.221", "12562565"]}, {"Citation": "Takayama S., Namiki T., Odaguchi H., Arita R., Hisanaga A., Mitani K., Ito T. Prevention and Recovery of COVID-19 Patients With Kampo Medicine: Review of Case Reports and Ongoing Clinical Trials. Front. Pharmacol. 2021;12:656246. doi: 10.3389/fphar.2021.656246.", "ArticleIdList": ["10.3389/fphar.2021.656246", "PMC8261067", "34248620"]}, {"Citation": "Takayama S., Kikuchi A., Makino T., Kainuma M., Namiki T., Ito T. Basic pharmacological mechanisms and clinical evidence of the efficacy of hochuekkito against infectious diseases and its potential for use against COVID-19. Tradit. Kampo Med. 2021;8:3\u201321. doi: 10.1002/tkm2.1264.", "ArticleIdList": ["10.1002/tkm2.1264"]}, {"Citation": "Kato Y. Case Management of COVID-19 (Secondary Version) JMA J. 2021;4:191\u2013197. doi: 10.31662/jmaj.2021-0036.", "ArticleIdList": ["10.31662/jmaj.2021-0036", "PMC8355701", "34414312"]}, {"Citation": "Sudre C.H., Murray B., Varsavsky T., Graham M.S., Penfold R.S., Bowyer R.C., Pujol J.C., Klaser K., Antonelli M., Canas L.S., et al. Attributes and predictors of long COVID. Nat. Med. 2021;27:626\u2013631. doi: 10.1038/s41591-021-01292-y.", "ArticleIdList": ["10.1038/s41591-021-01292-y", "PMC7611399", "33692530"]}, {"Citation": "Terasawa K. Evidence-based Reconstruction of Kampo Medicine: Part I-Is Kampo CAM? Evid.-Based Complementary Altern. Med. eCAM. 2004;1:11\u201316. doi: 10.1093/ecam/neh003.", "ArticleIdList": ["10.1093/ecam/neh003", "PMC442105", "15257321"]}, {"Citation": "Adams D., Wu T., Yang X., Tai S., Vohra S. Traditional Chinese medicinal herbs for the treatment of idiopathic chronic fatigue and chronic fatigue syndrome. Cochrane Database Syst. Rev. 2009:CD006348. doi: 10.1002/14651858.CD006348.pub2.", "ArticleIdList": ["10.1002/14651858.CD006348.pub2", "19821361"]}, {"Citation": "Traditional Chinese Medicine\u2014Controlled Vocabulary Index on Japanese Kampo Formulas and Indication Codes for Products. International Organization for Standardization; Geneva, Switzerland: 2018."}, {"Citation": "Chen R., Moriya J., Yamakawa J., Takahashi T., Li Q., Morimoto S., Iwai K., Sumino H., Yamaguchi N., Kanda T. Brain atrophy in a murine model of chronic fatigue syndrome and beneficial effect of Hochu-ekki-to (TJ-41) Neurochem. Res. 2008;33:1759\u20131767. doi: 10.1007/s11064-008-9620-1.", "ArticleIdList": ["10.1007/s11064-008-9620-1", "18317925"]}, {"Citation": "Chen R., Moriya J., Luo X., Yamakawa J., Takahashi T., Sasaki K., Yoshizaki F. Hochu-ekki-to combined with interferon-gamma moderately enhances daily activity of chronic fatigue syndrome mice by increasing NK cell activity, but not neuroprotection. Immunopharmacol. Immunotoxicol. 2009;31:238\u2013245. doi: 10.1080/08923970802391525.", "ArticleIdList": ["10.1080/08923970802391525", "18791913"]}, {"Citation": "Song Q.H., Toriizuka K., Jin G.B., Yabe T., Cyong J.C. Long term effects of Toki-shakuyaku-san on brain dopamine and nerve growth factor in olfactory-bulb-lesioned mice. Jpn. J. Pharmacol. 2001;86:183\u2013188. doi: 10.1254/jjp.86.183.", "ArticleIdList": ["10.1254/jjp.86.183", "11459120"]}, {"Citation": "Sat\u014d Y. Introduction to Kampo: Japanese Traditional Medicine. Elsevier; Tokyo, Japan: 2005. The Japan Society for Oriental Medicine. Diagnosis and treatment."}], "ReferenceList": []}], "History": [{"Year": "2022", "Month": "4", "Day": "1"}, {"Year": "2022", "Month": "5", "Day": "23"}, {"Year": "2022", "Month": "5", "Day": "26"}, {"Year": "2022", "Month": "6", "Day": "24", "Hour": "1", "Minute": "27"}, {"Year": "2022", "Month": "6", "Day": "25", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "6", "Day": "28", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "5", "Day": "28"}], "PublicationStatus": "epublish", "ArticleIdList": ["35743993", "PMC9227280", "10.3390/medicina58060730", "medicina58060730"]}}], "PubmedBookArticle": []}